These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22801851)

  • 61. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
    Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
    Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
    Azad R; Chandra P
    Indian J Ophthalmol; 2007; 55(4):319; author reply 320. PubMed ID: 17595491
    [No Abstract]   [Full Text] [Related]  

  • 63. Resolution of total retinal detachment in Coats' disease with intravitreal injection of bevacizumab.
    Zhao T; Wang K; Ma Y; Jiang YR
    Graefes Arch Clin Exp Ophthalmol; 2011 Nov; 249(11):1745-6. PubMed ID: 21080196
    [No Abstract]   [Full Text] [Related]  

  • 64. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity.
    Cheng HC; Lee SM; Hsieh YT; Lin PK
    Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Retinal detachment after bevacizumab.
    Arevalo JF; Sanchez JG; Saldarriaga L; Berrocal MH; Fromow-Guerra J; Morales-Canton V; Wu L; Maia M; Saravia MJ; Bareño J;
    Ophthalmology; 2011 Nov; 118(11):2304.e3-7. PubMed ID: 22047908
    [No Abstract]   [Full Text] [Related]  

  • 66. Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP screening (ITCROPS) data base report number 7.
    Chhablani J; Rani PK; Balakrishnan D; Jalali S
    Semin Ophthalmol; 2014 Jul; 29(4):222-5. PubMed ID: 24117452
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Will the BEAT-ROP study results really beat ROP?
    Raizada S; Kandari JA; Sabti KA
    Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):9288-9. PubMed ID: 22127432
    [No Abstract]   [Full Text] [Related]  

  • 68. Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
    Crouch ER; Kraker RT; Wallace DK; Holmes JM; Repka MX; Collinge JE; Bremer DL; Gray ME; Smith HA; Steinkuller PG;
    JAMA Ophthalmol; 2020 Jan; 138(1):14-20. PubMed ID: 31697304
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
    Mireskandari K; Collins ME; Tehrani N
    Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
    [No Abstract]   [Full Text] [Related]  

  • 70. Pain assessment in premature infants treated with intravitreal antiangiogenic therapy for retinopathy of prematurity under topical anesthesia.
    Castellanos MA; Schwartz S; Leal R; Chan RV; Quiroz-Mercado H
    Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):491-4. PubMed ID: 22619071
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bilateral Total Cataract After Intravitreal Bevacizumab Injection in Aggressive Posterior Retinopathy of Prematurity.
    Khokhar S; Chandra P; Gupta Y; Kumawat D; Dhull C
    J Pediatr Ophthalmol Strabismus; 2019 Mar; 56():e28-e30. PubMed ID: 30907975
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bevacizumab for retinopathy of prematurity.
    Reynolds JD
    N Engl J Med; 2011 Feb; 364(7):677-8. PubMed ID: 21323546
    [No Abstract]   [Full Text] [Related]  

  • 74. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
    Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
    Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Spectral-domain optical coherence tomography of the macula in preterm infants treated with bevacizumab for retinopathy of prematurity.
    Dorta P; Kychenthal A
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):321-6. PubMed ID: 25856817
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Alarming use of anti-VEGF therapy in premature infants].
    Hård AL; Hellström A
    Lakartidningen; 2011 Dec 7-13; 108(49):2600. PubMed ID: 22468401
    [No Abstract]   [Full Text] [Related]  

  • 78. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Hosseini H; Khalili MR; Nowroozizadeh S
    Retina; 2009 Apr; 29(4):562. PubMed ID: 19262431
    [No Abstract]   [Full Text] [Related]  

  • 79. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Nowroozzadeh MH
    Retina; 2009 Apr; 29(4):564-5; author reply 565-8. PubMed ID: 19262428
    [No Abstract]   [Full Text] [Related]  

  • 80. How Does the Standard of Care Evolve? Anti-Vascular Endothelial Growth Factor Agents in Retinopathy of Prematurity Treatment as an Example.
    Chiang MF
    Ophthalmology; 2018 Oct; 125(10):1485-1487. PubMed ID: 30243329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.